Daxor Corporation announced new data from the Mayo Clinic in Rochester, NY validating the benefits of the company's BVA-100 blood test for patients with heart failure. Data were presented at the Heart Failure Society of America (HFSA) Annual Scientific Meeting – which brought together the world's leading experts in heart failure on October 2nd, 2022, in Washington, DC. The study titled “Impact of Right Ventricular Dysfunction of Blood Volume Expansion in Heart Failure” measured blood volume in 139 heart failure patients at the time of hospital discharge (post-diuretic therapy and considered to have a normal blood volume) utilizing the Daxor BVA-100 diagnostic blood test.

Blood volume expansion was present in over 50% of the overall cohort with normal blood volume only present in 27% at the time of hospital discharge and a risk in particular for right ventricular dysfunction was highlighted as being particularly challenging. Despite treatment to resolve volume abnormalities, the study author noted “Persistent intravascular volume expansion is more common at the time of discharge despite diuretic intervention in heart failure.